Search

Catherine Spong, M.D., Chair and Professor of Obstetrics and Gynecology at UT Southwestern Medical Center, has been elected to the National Academy of Medicine (NAM) in recognition of her significant impact on the field of maternal-fetal medicine, her leadership in women’s health research, and her

A first responder for almost four decades, Roger McCurley had made hundreds of hospital runs while providing emergency service to people in the midst of the worst days of their lives.

Measuring levels of a specific brain wave could lead to more objective, definitive methods of diagnosing concussions.

New research from Children’s Medical Center Research Institute at UT Southwestern (CRI) found that different skeletal stem cell (SSC) populations contribute to repair of different kinds of bone injuries.

A UT Southwestern study of more than 1,300 pregnant women diagnosed with COVID-19 found that just 1 in 10 developed moderate, severe, or critical illness and that COVID-19 symptoms and severity were similar across all trimesters.

UT Southwestern sleep researcher Masashi Yanagisawa, M.D., Ph.D., has been awarded the Breakthrough Prize in Life Sciences for his discovery of the cause of narcolepsy.

UT Southwestern Medical Center is the No. 1 hospital in Dallas-Fort Worth – the nation’s fourth-largest metro area – for the sixth consecutive year and ranks among the top hospitals nationally in nine specialties ranging from brain to heart to cancer care.

Todd Aguilera, M.D., Ph.D., Assistant Professor of Radiation Oncology and member of the Experimental Therapeutics Program in the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center, has been named one of 11 inaugural Cancer Moonshot Scholars. The national program

Patients with neuropathic bladder (NB), a condition in which nerve damage affects bladder function, have a significantly higher risk of joint infections, blood clots, and other adverse events after receiving total hip replacement (THR), UT Southwestern Medical Center researchers found.

The U.S. Food & Drug Administration has expanded the approved use of belzutifan for treatment of metastatic kidney cancer, another milestone for the novel, first-in-class kidney cancer drug arising from scientific discoveries at UT Southwestern Medical Center.